Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial.

Neuro Oncol · 2023 · PMC10237418 · PMID 36640127

Europe PMC DOI

hedged sentence

0.2150

closest p · 4.3× alpha

0.2150

boldest claim

The sentences

did not reach statistical significanceP = .215not close (p > 0.1)

IL4R High patients showed an mOS of 15.02 months and IL4R Low patients showed an mOS of 8.4 months, although this difference did not reach statistical significance ( P = .215) ( Figure 1 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.